TYPE A2 BOTULINUM TOXIN PREPARATION
    2.
    发明申请
    TYPE A2 BOTULINUM TOXIN PREPARATION 审中-公开
    A2型BOTULINUM毒素制剂

    公开(公告)号:US20110033431A1

    公开(公告)日:2011-02-10

    申请号:US12935769

    申请日:2009-03-31

    摘要: A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.

    摘要翻译: 一种用于患有来自A1型肉毒毒素(A1型肉毒杆菌毒素)的肉毒毒素中和抗体的患者的药物制剂,所述制剂包含来自A2型肉毒毒素(A2NTX)的150kDa A型神经毒素作为活性成分, ; 用于治疗患有肌肉过度活动的疾病的药物,所述疾病用于患有A1型肉毒杆菌毒素的中和抗体的患者,所述药物包含所述A2NXX的活性成分; 用于治疗对A1型肉毒杆菌毒素具有中和抗体的患者的方法,所述方法包括向患者施用所述A2NXX; 以及在具有所述中和抗体的患者中使用A2NTX的方法。 根据本发明,当患者用包含A1型肉毒杆菌毒素的药物制剂治疗时,可以解决由中和抗体对产生的A1型肉毒杆菌毒素引起的临床反应降低的问题。

    Human activated protein C and process for preparing same
    3.
    发明授权
    Human activated protein C and process for preparing same 失效
    人活化蛋白C及其制备方法

    公开(公告)号:US5831025A

    公开(公告)日:1998-11-03

    申请号:US637662

    申请日:1996-04-29

    摘要: A human Activated Protein C preparation with a high specific activity of 3500 U/mg or more and substantially free from thrombin or other proteases which can convert Protein C into Activated Protein C is provided. A process for preparing this human Activated Protein C, which involves, contacting a solution of human Activated Protein C, after activation of Protein C with thrombin or other activating protease, with a cation exchanger to allow for adsorption of both thrombin or another activating protease and Activated Protein C to the cation exchanger followed by elution of the human Activated Protein C alone.

    摘要翻译: PCT No.PCT / JP94 / 01807 Sec。 371日期:1996年4月29日 102(e)日期1996年4月29日PCT 1994年10月27日PCT公布。 公开号WO95 / 11966 日期1996年5月4日提供具有3500U / mg以上的高比活性和基本上不含可将蛋白C转化成活化蛋白C的凝血酶或其它蛋白酶的人活化蛋白C制剂。 制备这种人活化蛋白C的方法,其涉及在将蛋白C与凝血酶或其它活化蛋白酶一起活化后将人活化蛋白C的溶液与阳离子交换剂接触以允许凝血酶或另一活化蛋白酶的吸附, 将活化的蛋白C转移至阳离子交换剂,然后单独洗脱人活化蛋白C。